Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Inclusion Criteria

• Subject is able to provide written, informed consent and comply with the study protocol.
• Subject is at least 18 years of age.
• Subject has a diagnosis of plaque-type palmar and/or plantar psoriasis.
• Patient has at least one psoriatic plaque outside of the palms and soles or psoriatic nail findings.
• Subject has a ppPGA ≥ 3 at screening/baseline visit.
• Subject is using adequate birth control during the study period as defined as follows:
• Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR
• Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.

OR

• Option 3: Abstinence from sex when it is a lifestyle choice, and not just a social circumstance.

Exclusion Criteria

• Subject is not able to provide written, informed consent and comply with the study protocol.
• Subject is less than 18 years of age.
• Subject has non-plaque type psoriasis on the hands and/or feet.
• Patient does not have any evidence of psoriasis elsewhere.
• Subject has concurrent cutaneous disease affecting the hands and/or feet that would interfere with assessments.
• Subject has a ppPGA < 3 at screening/baseline visit.
• Subject refuses to discontinue concomitant prescription medications on hands and/or feet.
• Subject has used topical prescription treatments or received phototherapy treatment for psoriasis within 2 weeks of screening/baseline visit.
• Subject has used intralesional kenalog within 4 weeks of screening/baseline visit.
• Subject has taken oral treatments for psoriasis within 4 weeks of screening/baseline visit.
• Subject has received any treatment with biologic medications within 5 half-lives (if known) or 16 weeks prior to screening/baseline, whichever is longer.
• Subject refuses to use adequate birth control during the duration of the study period.
• Subject is currently pregnant or breastfeeding.